Corner Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$16.8M
- Investors
-
5
Corner Therapeutics General Information
Description
Provider of biotechnology research services intended to stimulate exceptional memory T cells for lifelong immunity. The company's technologies offer a versatile dendritic cell hyperactivation (hDC) platform that induces exceptional T-cell responses, providing robust and durable immunity against a virtually unbounded range of cancers and infectious diseases, enabling healthcare providers to promote durable immunity and ensure the apex of immune regulators.
Contact Information
Website
cornertx.comCorporate Office
- 300 North Beacon Street
- Building 39, Suite 202
- Watertown, MA 02472
- United States
Corporate Office
- 300 North Beacon Street
- Building 39, Suite 202
- Watertown, MA 02472
- United States
Corner Therapeutics Timeline
Corner Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 20-Oct-2025 | $16.8M | Completed | Pre-Clinical Trials | ||
| 2. Later Stage VC | 11-Aug-2025 | Completed | Pre-Clinical Trials | |||
| 1. Grant | 01-Nov-2023 | $1.77M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Corner Therapeutics Patents
Corner Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226710-A1 | Adjuvant for adoptive cell therapy | Pending | 23-Apr-2025 | ||
| WO-2026226703-A1 | Lipid nanoparticles loaded with a cyclic gmp-amp synthase (cgas) expression construct, for use in the treatment of a solid tumour | Pending | 23-Apr-2025 | ||
| WO-2026207248-A1 | Mrna immunomodulators | Pending | 27-Mar-2025 | ||
| WO-2026198437-A1 | Therapeutic human papillomavirus mrna vaccine and adjuvant for same | Pending | 17-Mar-2025 | ||
| WO-2025221606-A1 | Lipids for hyperactivation of mammalian dendritic cells | Pending | 16-Apr-2024 | A61K45/06 |
Corner Therapeutics Signals
Corner Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cockrell Interests | Family Office | Minority | ||
| Sandia Holdings | Corporation | Minority | ||
| Tanis Venture Management | Venture Capital | Minority | ||
| Ziff Capital Partners | Family Office | Minority | ||
| Gates Foundation | Not-For-Profit Venture Capital | Minority |
Corner Therapeutics FAQs
-
When was Corner Therapeutics founded?
Corner Therapeutics was founded in 2020.
-
Where is Corner Therapeutics headquartered?
Corner Therapeutics is headquartered in Watertown, MA.
-
What is the size of Corner Therapeutics?
Corner Therapeutics has 18 total employees.
-
What industry is Corner Therapeutics in?
Corner Therapeutics’s primary industry is Biotechnology.
-
Is Corner Therapeutics a private or public company?
Corner Therapeutics is a Private company.
-
What is Corner Therapeutics’s current revenue?
The current revenue for Corner Therapeutics is .
-
How much funding has Corner Therapeutics raised over time?
Corner Therapeutics has raised $75.3M.
-
Who are Corner Therapeutics’s investors?
Cockrell Interests, Sandia Holdings, Tanis Venture Management, Ziff Capital Partners, and Gates Foundation have invested in Corner Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process